Overview of the Acquisition
The Competition Commission of Pakistan (CCP) has approved the acquisition of Novartis Pharma (Pakistan) Limited (Novartis Pakistan) by International Investment II Limited (IIL). This decision was made after the completion of a phase-I competition assessment under Section 11 of the Competition Act, 2010, and the Competition (Merger Control) Regulations, 2016. IIL, an investment holding company based in Hong Kong and part of the Getz Group, submitted a pre-merger application to the CCP. The transaction involves the transfer of control of Novartis Pakistan from its existing parent entities, Novartis AG and Novartis Pharma AG, to IIL through a share purchase agreement.
Novartis Pakistan is a leading pharmaceutical company that operates across various therapeutic classes. It is involved in the manufacture, import, marketing, and distribution of medicines throughout Pakistan. The acquisition marks a significant development in the country’s pharmaceutical sector, as IIL already has a presence in Pakistan through its subsidiaries, Getz Pharma (Private) Limited and Scilife Pharma (Private) Limited.
Phase-I Review Process
During the Phase-I review, the CCP assessed whether the transaction could lead to the creation or strengthening of a dominant position or otherwise substantially reduce competition in the relevant markets. The commission defined the relevant markets at the therapeutic class level, as there is limited substitutability across different medical categories.
The Commission noted that there are some overlaps between Novartis Pakistan and the Acquirer Group in certain therapeutic classes, such as diabetes, anti-rheumatics, anti-epileptics, and cardiovascular agents. However, the combined market shares in these areas were not high enough to raise concerns about competition. Based on this evaluation, the CCP concluded that the transaction does not create or strengthen a dominant position in any relevant market and is unlikely to significantly reduce competition in Pakistan.
Legal Approval and Implications
As a result of the assessment, the acquisition has been authorized under Section 31(1)(d)(i) of the Competition Act, 2010. This approval allows IIL to proceed with the acquisition of Novartis Pakistan, which could have long-term implications for the pharmaceutical industry in Pakistan.
The decision reflects the CCP’s commitment to ensuring fair competition in the market while allowing for legitimate business growth. By carefully analyzing the potential impact of the transaction, the commission has ensured that the interests of consumers and the broader market remain protected.
Key Points of the Transaction
- Acquisition Details: The acquisition involves the transfer of control of Novartis Pakistan from Novartis AG and Novartis Pharma AG to IIL.
- Market Analysis: The CCP examined the potential for the transaction to affect competition in the pharmaceutical sector.
- Therapeutic Class Focus: The relevant markets were defined at the therapeutic class level due to the lack of substitutability between different medical categories.
- Overlaps Considered: While there are overlaps in specific therapeutic areas, the combined market shares do not pose a threat to competition.
- Legal Basis: The approval was granted under Section 31(1)(d)(i) of the Competition Act, 2010.
Conclusion
The approval of the acquisition by the CCP underscores the importance of maintaining competitive markets while supporting business expansion. With IIL’s existing presence in Pakistan through its subsidiaries, the acquisition of Novartis Pakistan is expected to contribute to the growth of the pharmaceutical industry. The decision highlights the balance between fostering business opportunities and safeguarding market fairness. As the transaction moves forward, it will be important to monitor its impact on the sector and ensure continued compliance with competition regulations.